申请人:Takeda Pharmaceutical Company Limited
公开号:US20140228409A1
公开(公告)日:2014-08-14
The present invention provides a fused heterocyclic compound having an RORγt inhibitory action. The present invention relates to a compound represented by the formula (I′):
wherein each symbol is as defined in the specification, provided that 2-(2-((4-cyanophenyl)amino)-2-oxoethoxy)-N-(9-ethyl-9H-carbazol-3-yl)acetamide and N-(4-cyanophenyl)-N′-(9-ethyl-9H-carbazol-3-yl)-3-methylpentanediamide are excluded, or a salt thereof.
本发明提供了一种具有RORγt抑制作用的融合杂环化合物。本发明涉及一种由式(I')表示的化合物:其中每个符号如规范中所定义,前提是2-(2-((4-氰基苯基)氨基)-2-氧代乙氧基)-N-(9-乙基-9H-咔唑-3-基)乙酰胺和N-(4-氰基苯基)-N'-(9-乙基-9H-咔唑-3-基)-3-甲基戊二酰胺被排除,或其盐。